PT1524968E - Formulação farmacêutica oral na forma de uma pluralidade de microcápsulas para libertação prolongada de princípios activos com baixa solubilidade - Google Patents

Formulação farmacêutica oral na forma de uma pluralidade de microcápsulas para libertação prolongada de princípios activos com baixa solubilidade Download PDF

Info

Publication number
PT1524968E
PT1524968E PT03750852T PT03750852T PT1524968E PT 1524968 E PT1524968 E PT 1524968E PT 03750852 T PT03750852 T PT 03750852T PT 03750852 T PT03750852 T PT 03750852T PT 1524968 E PT1524968 E PT 1524968E
Authority
PT
Portugal
Prior art keywords
microcapsules
active principle
core
release
low solubility
Prior art date
Application number
PT03750852T
Other languages
English (en)
Inventor
Remi Meyrueix
Florence Guimberteau
Catherine Castan
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of PT1524968E publication Critical patent/PT1524968E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT03750852T 2002-07-26 2003-07-28 Formulação farmacêutica oral na forma de uma pluralidade de microcápsulas para libertação prolongada de princípios activos com baixa solubilidade PT1524968E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0209532A FR2842736B1 (fr) 2002-07-26 2002-07-26 Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)

Publications (1)

Publication Number Publication Date
PT1524968E true PT1524968E (pt) 2008-03-13

Family

ID=30011529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03750852T PT1524968E (pt) 2002-07-26 2003-07-28 Formulação farmacêutica oral na forma de uma pluralidade de microcápsulas para libertação prolongada de princípios activos com baixa solubilidade

Country Status (17)

Country Link
US (1) US8652523B2 (pt)
EP (1) EP1524968B1 (pt)
JP (2) JP5430815B2 (pt)
KR (1) KR20050026515A (pt)
CN (1) CN1678295B (pt)
AT (1) ATE381927T1 (pt)
AU (1) AU2003269067B2 (pt)
BR (1) BR0312995A (pt)
CA (1) CA2493453C (pt)
DE (1) DE60318316T2 (pt)
ES (1) ES2298551T3 (pt)
FR (1) FR2842736B1 (pt)
IL (1) IL166383A0 (pt)
MX (1) MXPA05001077A (pt)
PT (1) PT1524968E (pt)
WO (1) WO2004010983A2 (pt)
ZA (1) ZA200500693B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) * 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
ES2655622T3 (es) * 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
WO2020130649A1 (ko) * 2018-12-19 2020-06-25 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2313915A1 (fr) 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
GB8414221D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
LU85943A1 (fr) 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
IT1227899B (it) 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
FI922107A0 (fi) * 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition och foerfarande.
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
JPH09188617A (ja) 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
NZ333514A (en) 1996-06-28 2000-05-26 Schering Corp Oral pharmaceutical composition comprising a triazole antifungal compound
CA2275475A1 (en) 1996-12-19 1998-06-25 Hiroshi Kikuchi Pharmaceutical composition for oral administration
CA2326456C (en) 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
ES2157731B1 (es) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
WO2002085335A1 (en) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin

Also Published As

Publication number Publication date
US8652523B2 (en) 2014-02-18
FR2842736A1 (fr) 2004-01-30
KR20050026515A (ko) 2005-03-15
WO2004010983A2 (fr) 2004-02-05
EP1524968A2 (fr) 2005-04-27
ES2298551T3 (es) 2008-05-16
FR2842736B1 (fr) 2005-07-22
WO2004010983A3 (fr) 2004-04-08
IL166383A0 (en) 2006-01-16
MXPA05001077A (es) 2005-06-06
DE60318316D1 (de) 2008-02-07
CA2493453C (fr) 2012-05-22
EP1524968B1 (fr) 2007-12-26
ZA200500693B (en) 2006-07-26
AU2003269067A1 (en) 2004-02-16
US20060165809A1 (en) 2006-07-27
JP5430815B2 (ja) 2014-03-05
JP2006500332A (ja) 2006-01-05
CN1678295B (zh) 2010-04-28
BR0312995A (pt) 2005-06-28
CA2493453A1 (fr) 2004-02-05
JP2014005289A (ja) 2014-01-16
CN1678295A (zh) 2005-10-05
ATE381927T1 (de) 2008-01-15
DE60318316T2 (de) 2008-12-11
AU2003269067B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
ZA200500693B (en) Oral pharmaceutical formualtion in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility
WO2004010984A3 (fr) Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os
Lu et al. A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent
US9572773B2 (en) Layered drug delivery device
Fulzele et al. Polymerized rosin: novel film forming polymer for drug delivery
Maheshwari et al. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin
EP2381931B1 (fr) Composition comprenant un actif de faible solubilité aqueuse
CA2554052A1 (en) Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile
CA2769046A1 (en) Coating agent for the dip coating of capsule halves
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
HRP20140097T1 (hr) Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
CA2476496A1 (en) Controlled release dosage forms
Nan et al. Porous silicon oxide–PLGA composite microspheres for sustained ocular delivery of daunorubicin
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
ATE522204T1 (de) Beschichtete pellets
DE60200202D1 (de) Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung
Garg et al. Effect of formulation parameters on the release characteristics of propranolol from asymmetric membrane coated tablets
Sangeetha et al. Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis
AU2012358032A1 (en) Drug-coated medical devices
JP6780412B2 (ja) コーティング組成物ならびにコーティング製剤及びその製造方法
Muschert et al. Improved long term stability of aqueous ethylcellulose film coatings: importance of the type of drug and starter core
NO331643B1 (no) Mikrogranuler som ikke er loselige i magesaft, fremgangsmater for a oppna det samme og farmasoytiske preparater
TW201731492A (zh) 防沾黏材
Zaid et al. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric.
WO2005070392A3 (en) Non-lamellar compositions of dioleoyl phosphatidylethanolamine and polysorbate 80